Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Systematic review and metaanalysis on nonclassic cardiovascular biomarkers after hypertensive pregnancy disorders.

Visser S, Hermes W, Ket JC, Otten RH, van Pampus MG, Bloemenkamp KW, Franx A, Mol BW, de Groot CJ.

Am J Obstet Gynecol. 2014 Oct;211(4):373.e1-9. doi: 10.1016/j.ajog.2014.03.032. Review.

PMID:
24637129
2.

Homocysteinemia After Hypertensive Pregnancy Disorders at Term.

Visser S, Hermes W, Blom HJ, Heijboer AC, Franx A, Van Pampus MG, Bloemenkamp KW, Koopmans C, Mol BW, De Groot CJ.

J Womens Health (Larchmt). 2015 Jun;24(6):524-9. doi: 10.1089/jwh.2015.5201.

PMID:
26070038
3.

Biochemical cardiovascular risk factors after hypertensive pregnancy disorders: a systematic review and meta-analysis.

Hermes W, Ket JC, van Pampus MG, Franx A, Veenendaal MV, Kolster C, Tamsma JT, Bloemenkamp KW, Ponjee G, van der Hout E, Ten Horn H, Loix S, Mol BW, de Groot CJ.

Obstet Gynecol Surv. 2012 Dec;67(12):793-809. doi: 10.1097/OGX.0b013e31827682fc. Review.

PMID:
23233052
4.

Cardiovascular risk estimation in women with a history of hypertensive pregnancy disorders at term: a longitudinal follow-up study.

Hermes W, Tamsma JT, Grootendorst DC, Franx A, van der Post J, van Pampus MG, Bloemenkamp KW, Porath M, Mol BW, de Groot CJ.

BMC Pregnancy Childbirth. 2013 Jun 4;13:126. doi: 10.1186/1471-2393-13-126.

5.

Hypertension in pregnancy is associated with elevated homocysteine levels later in life.

White WM, Turner ST, Bailey KR, Mosley TH Jr, Kardia SL, Wiste HJ, Kullo IJ, Garovic VD.

Am J Obstet Gynecol. 2013 Nov;209(5):454.e1-7. doi: 10.1016/j.ajog.2013.06.030.

6.

Maternal plasma homocysteine concentrations are not increased in twin pregnancies.

Powers RW, Dunbar MS, Laivuori HM, Harger GF, Lykins DL, Roberts JM.

Hypertens Pregnancy. 2005;24(1):49-58.

PMID:
16036390
7.

Longitudinal analysis of cardiovascular risk parameters in women with a history of hypertensive pregnancy disorders: the Doetinchem Cohort Study.

Drost JT, van der Schouw YT, Maas AH, Verschuren WM.

BJOG. 2013 Oct;120(11):1333-9. doi: 10.1111/1471-0528.12254.

8.

Markers of cardiovascular disease risk after hypertension in pregnancy.

Mangos GJ, Spaan JJ, Pirabhahar S, Brown MA.

J Hypertens. 2012 Feb;30(2):351-8. doi: 10.1097/HJH.0b013e32834e5ac7.

PMID:
22179081
9.

Relationships between maternal novel adipocytokines and bone biomarkers in complicated by gestational hypertensive disorders and normal pregnancies.

Briana DD, Boutsikou M, Boutsikou T, Malamitsi-Puchner A.

J Matern Fetal Neonatal Med. 2013 Aug;26(12):1219-22. doi: 10.3109/14767058.2013.775420.

PMID:
23406471
10.

Angiogenic factors in women ten years after severe very early onset preeclampsia.

Gaugler-Senden IP, Tamsma JT, van der Bent C, Kusters R, Steegers EA, de Groot CJ.

PLoS One. 2012;7(8):e43637. doi: 10.1371/journal.pone.0043637.

11.

Cardiovascular risk factors in women who had hypertensive disorders late in pregnancy: a cohort study.

Hermes W, Franx A, van Pampus MG, Bloemenkamp KW, Bots ML, van der Post JA, Porath M, Ponjee GA, Tamsma JT, Mol BW, de Groot CJ.

Am J Obstet Gynecol. 2013 Jun;208(6):474.e1-8. doi: 10.1016/j.ajog.2013.02.016.

12.

Homocysteine plasma concentration levels for the prediction of preeclampsia in women with chronic hypertension.

Zeeman GG, Alexander JM, McIntire DD, Devaraj S, Leveno KJ.

Am J Obstet Gynecol. 2003 Aug;189(2):574-6.

PMID:
14520237
13.

Total plasma fibronectin as a marker of pregnancy-induced hypertensive disorders: a longitudinal study.

Paarlberg KM, de Jong CL, van Geijn HP, van Kamp GJ, Heinen AG, Dekker GA.

Obstet Gynecol. 1998 Mar;91(3):383-8.

PMID:
9491865
14.

Hypertensive disorders in pregnancy and subsequently measured cardiovascular risk factors.

Magnussen EB, Vatten LJ, Smith GD, Romundstad PR.

Obstet Gynecol. 2009 Nov;114(5):961-70. doi: 10.1097/AOG.0b013e3181bb0dfc.

PMID:
20168095
15.

Leptin and interferon-gamma as possible predictors of cesarean section among women with hypertensive disorders of pregnancy.

Rytlewski K, Huras H, Kuśmierska-Urban K, Gałaś A, Reroń A.

Med Sci Monit. 2012 Aug;18(8):CR506-511.

16.

[Leptin as a possible marker of augmented metabolic risk during pregnancy].

Salvatores M, Gennarelli G, Menato G, Massobrio M.

Minerva Ginecol. 2006 Feb;58(1):1-10. Italian.

PMID:
16498365
17.

Hypertension in pregnancy and endothelial activation: An emerging risk factor for cardiovascular disease.

Lazzarin N, Desideri G, Ferri C, Valensise H, Gagliardi G, Tiralongo GM, Manfellotto D.

Pregnancy Hypertens. 2012 Oct;2(4):393-7. doi: 10.1016/j.preghy.2012.02.002.

PMID:
26105609
18.

Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction.

Hogg BB, Tamura T, Johnston KE, Dubard MB, Goldenberg RL.

Am J Obstet Gynecol. 2000 Oct;183(4):805-9.

PMID:
11035317
19.

Homocysteine and cellular fibronectin are increased in preeclampsia, not transient hypertension of pregnancy.

Powers RW, Evans RW, Ness RB, Crombleholme WR, Roberts JM.

Hypertens Pregnancy. 2001;20(1):69-77.

PMID:
12044315
20.

Pulse pressure and risk of preeclampsia: a prospective study.

Thadhani R, Ecker JL, Kettyle E, Sandler L, Frigoletto FD.

Obstet Gynecol. 2001 Apr;97(4):515-20.

PMID:
11275020

Supplemental Content

Support Center